Medtronic Plc

Global C-suite leader brings decades of spinal innovation and PMA experience to support Dymicron's next stage of growth OREM, Utah, Feb. 19, 2026 /PRNewswire/ -- Dymicron®, a privately held medical device company advancing next-generation spinal motion-preservation technology, today announced the appointment of Peter Wehrly, one of the spinal industry's most seasoned C-suite executives, to its Board of Directors. Mr. Wehrly brings more than forty years of leadership experience, including roles as CEO, President, Chairman, and global P&L leader across multibillion-dollar medical technology organizations. His appointment represents a significant strategic milestone for Dymicron as it progresses the Triadyme-C® cervical disc through its U.S. PMA pathway and expands international commercialization. Mr. Wehrly has built a distinguished career leading major medical device companies through regulatory approval, clinical evidence generation, and global market adoption. His executive experience includes serving as CEO and Chairman of Synaptive Medical, U.S. President and Board Member at Premia Spine, and Group President for Covidien's extensive global operations across Western Europe, Japan, Canada, Australia, and New Zealand. He previously held senior leadership roles at Medtronic Spine & Biologics, Johnson & Johnson, Vivex Biologics, and Titan Spine, consistently steering innovation-driven organizations through growth, turnaround, operational integration, and successful commercialization of advanced spine technologies — experience that aligns precisely with Dymicron's current trajectory. "Peter is widely recognized as a transformative leader in the spinal medical device sector," said Alan S. Layton, Chief Executive Officer and Chairman of Dymicron. "His rare blend of PMA experience, global regulatory insight, and commercialization success will help guide Triadyme-C through its clinical and regulatory milestones. His judgment and strategic perspective will be invaluable as we expand surgeon engagement, strengthen our clinical evidence, and accelerate global adoption." Mr. Wehrly expressed strong enthusiasm for joining the board, stating: "Dymicron's Triadyme-C technology represents a true leap forward in motion preservation, combining advanced biomechanics with a bearing surface that addresses longstanding wear-debris challenges in cervical arthroplasty. The company's commitment to rigorous clinical validation and global commercialization strongly aligns with my professional focus. I look forward to supporting the leadership team as Dymicron advances toward PMA approval and broadens its global impact." His appointment follows a period of meaningful momentum for Dymicron, including the FDA's approval of the company's IDE and the initiation of enrollment in its pivotal U.S. PMA clinical study. With Mr. Wehrly's addition to the Board, Dymicron strengthens its strategic position and reinforces its commitment to delivering the next generation of spinal motion-preservation solutions. About the Triadyme–C The Triadyme-C is a next-generation, motion-preserving cervical artificial disc made of Adymite polycrystalline diamond, one of the most wear-resistant materials known to man. As a result, the Tri­adyme-C produces virtually no detectable wear debris, minimizing the risk of any wear debris-related complications, and optimizing performance for the lifetime of the patient. The Triadyme-C's patented tri-lobe articulation surfaces are designed to mimic the natural kinematics and motion of a spinal disc. About Dymicron Dymicron is a privately held, innovation-driven medical device company based in Orem, Utah. The Company has developed a revolutionary, next-generation total disc replacement system for the cervical spine engineered from Adymite, their proprietary, medical-grade polycrystalline diamond material. To learn more, visit . For more information, please contact: Curt Ence Chief Financial Officer Dymicron 1186 South 1680 West Orem, UT 84058 Email: [email protected] SOURCE Dymicron Inc. 21% more press release views with Request a Demo

Mason, Ohio-based AtriCure, a specialist in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management, saw substantial revenue growth in Q4 2025. The company saw a 13.1% year-over-year growth for the quarter, reaching worldwide revenues of $140.5 million. Full year 2025 worldwide revenue reached $534.5 million, an increase of 14.9% year-over-year. AtriCure credits its growth to a few factors, including expanded use of new products, including cryoSPHERE MAX and AtriClip FLEX-Mini, and the continued adoption of EnCompass clamp. “Our 2025 performance reflects strong execution and continued momentum in our business. We delivered 15% revenue growth for the year and strengthened profitability while advancing key innovation and clinical initiatives, including enrollment of our LeAAPs clinical trial, and the initiation of our BoxX-NoAF trial, that position the company for sustained value creation,” Michael Carrel, President and Chief Executive Officer at AtriCure, said during the company’s earnings call. “Entering 2026, we remain focused on driving durable growth, expanding margins and executing on strategic priorities that enhance AtriCure’s leadership position across our markets.” As a result of the revenue growth, the company has updated its full year 2026 revenue projection from approximately $600 million to $610 million, reflecting growth of approximately 12% to 14% over full year 2025. Following the earnings call, shares of ATRC rose to 7% to $35.26 apiece in pre-market trading on February 18. They had ticked up 1% to $32.97 after hours yesterday, February 17, after the company first reported the results. In pain management, AtriCure saw a 24% growth in Q4 revenue, credited to the continued adoption of the cryoSPHERE MAX device, with the company ending the year with roughly 500 U.S. accounts using cryoSPHERE MAX and surpassed 100,000 patients treated with cryoSPHERE probes since the franchise launched in 2019. Revenues also grew 15% in appendage management, with open left atrial appendage growth outpacing minimally invasive devices. The AtriClip FLEX MINI and AtriClip PRO MINI were credited as key drivers due to the low profile of the “mini” devices. The company exited 2025 with more than 300 active accounts purchasing FLEX MINI, which contributed 18% of worldwide left atrial appendage management revenue in 2025. In open AFib ablation, revenue grew 17%, primarily driven by the Encompass clamp. Encompass was present in more than 830 accounts worldwide, and U.S. open ablation sales were $143.8 million, up 16.3% year over year, with Encompass contributing more than 60% of U.S. open ablation revenue in 2025. On the other hand, in the earnings call, Carrel described AtriCure’s AFib treatment franchise as a “headwind,” under pressure from PFA growth in the U.S. MIS revenue for the company was down 31.2% in 2025, with customers prioritizing PFA catheters. The company also noted it has several clinical trials in the pipeline, on top of new product developments for 2026. Its ongoing LEAPS trial, which currently has 6,573 patients enrolled, is aimed at expanding treatment in cardiac surgery patients without pre-existing AFib. Its 960 patient BOX X NoAF trial is evaluating ablation intended to reduce postoperative AFib in cardiac surgery patients without pre-existing AFib. ArtiCure is also working on a dual-energy EnCompass clamp intended to shorten RF ablation times and add PFA as a complementary energy source. As ArtiCure starts its own expansion into PFA, it will likely continue to be a headwind for the company, as there are a number of strong existing competitors in the space. Medtronic just s aw its PFA portfolio in the U.S. grow 137% in the U.S., while Boston Scientific and Abbott have also made major strides in the space. In addition, Edwards Lifesciences recently announced its plans to introduce a surgical left atrial appendage closure device this year. This device had been anticipated by investors for many months. “While we acknowledge competition is an overhang on ATRC's stock, we emphasize that ATRC had been anticipating this competition and that the company successfully fended off a prior competitive entrant over the past couple of years. ATRC believes that their products and expertise in ablation as well as appendage management offer an advantage in concomitant valve procedures. We expect this expertise to be part of ATRC's competitive moat,” BTIG analysts wrote. As a result of ArtiCure outpacing previous analyst expectations, and increasing its revenue projections for 2026, analysts at BTIG have reiterated their rating of the company as “buy.” “ATRC shares were impacted last week by the announcement of emerging competition for AtriClip. However, this competition was expected eventually, and we believe the co. will be ready to combat share loss, particularly with competitive barriers like ablation expertise, a commitment to clinical R&D work, and a long-standing relationship with customers,” analysts wrote. “ATRC's fundamentals across its main franchises remain strong, and profitability metrics continue to exceed long-range targets. We acknowledge sentiment around competition but view ATRC as undervalued.”

Danaher to Buy Masimo for $9.9B Masimo has agreed to be acquired by Danaher in a cash deal valued at $9.9 billion. Masimo will become a standalone business unit and brand within Danaher’s diagnostics segment. The acquisition is expected to close in the second half of 2026. Medtronic Is Going Through a Growth Spurt Medtronic achieved 8.7% revenue growth in its fiscal third quarter, reaching $9 billion for its highest growth in 10 quarters. Among other factors, the growth was driven by the company’s cardiac ablation solutions and diabetes segments. VB Spine Is Becoming the Spine Company to Watch VB Spine is quickly becoming a dominant player in the spine market. The company has acquired exclusive rights to Augmedics’ xvision spine system, adding augmented reality navigation to its growing enhanced visualization portfolio.